Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
'"`UNIQ--vote-00000178-QINU`"', '"`UNIQ--vote-00000179-QINU`"' (1) ·
'"`UNIQ--vote-000003D3-QINU`"', '"`UNIQ--vote-000003D4-QINU`"' (1) ·
'"`UNIQ--vote-00000805-QINU`"', '"`UNIQ--vote-00000806-QINU`"' (1) ·
'"`UNIQ--vote-00000C2E-QINU`"', '"`UNIQ--vote-00000C2F-QINU`"', '"`UNIQ--vote-00000C30-QINU`"', '"`UNIQ--vote-00000C31-QINU`"' (1)
10-20 mg PO once daily in the evening (40 mg starting allowed for high CV risk) (1) ·
2.5 mg PO once daily (1.25 mg in CHF or volume depletion); titrate to 5-10 mg/d (1) ·
20 mg PO once daily with the evening meal; titrate to 40-80 mg/d (1) ·
40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions) (1)
20 mg/d (hypertension); 10 mg/d (other indications typical) (1) ·
40 mg/d standard; 80 mg/d restricted to patients tolerating 80 mg for ≥12 months without myopathy (post-SEARCH 2011 FDA restriction) (1) ·
80 mg/d (1) ·
80 mg/d (40 mg/d if combined with diltiazem, verapamil, danazol; lower limits with various interactions) (1)
~13-17 hours (ramiprilat, the active metabolite)'"`UNIQ--ref-00000C32-QINU`"' (1) ·
~2 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect lasts 24 hours via target turnover'"`UNIQ--ref-0000017A-QINU`"' (1) ·
~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) ·
~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-00000807-QINU`"' (1)
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' (1) ·
<5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)'"`UNIQ--ref-0000017B-QINU`"' (1) ·
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) ·
~28% (oral; food slows but does not reduce absorption)'"`UNIQ--ref-00000C33-QINU`"' (1)
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension'"`UNIQ--ref-00000C34-QINU`"' (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3)
Showing below up to 4 results in range #1 to #4.


